Novavax on Monday announced that its Covid vaccine — NVX-CoV2373 —demonstrated 100% protection against moderate and severe disease with 90.4% efficacy overall in phase-3 trial. “NVX-CoV2373, recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial,” Novavax said in a press statement on June 14.
It said the study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.
Also Read | Apollo Hospital MD on her Covid treatment: ‘Cocktail therapy made a dramatic difference’
Novavax CEO and President Stanley C. Erck said that Novavax was one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines.
“These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection,” he said.
Also Read | Covaxin trials on children aged 6-12: AIIMS Delhi to start recruitment from tomorrow
The company said that it “intends to file for regulatory authorizations in the third quarter, upon completion of the final phases of process qualification and assay validation needed to meet chemistry, manufacturing and controls (CMC) requirements.”
“Upon regulatory approvals, Novavax remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021” it said.
“PREVENT-19 confirms that NVX-CoV2373 offers a reassuring tolerability and safety profile,” said Gregory M. Glenn, M.D., President of Research and Development, Novavax.
“”These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus. Our vaccine will be a critical part of the solution to COVID-19 and we are grateful to the study participants and trial staff who made this study possible, as well as our supporters, including the U.S. Government,” Glenn said.
Never miss a story! Stay connected and informed with Mint.
Download
our App Now!!
